Connor, Clark & Lunn Investment Management (CC&L)
KROS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Keros Therapeutics KROS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.85M Sell
257,884
-63,462
-20% -$980K 0.01% 854
2025
Q4 		$6.54M Sell
321,346
-13,808
-4% -$242K 0.02% 575
2025
Q3 		$5.3M Buy
335,154
+69,447
+26% +$1.03M 0.02% 561
2025
Q2 		$3.55M Buy
265,707
+137,604
+107% +$1.86M 0.01% 678
2025
Q1 		$1.31M Buy
128,103
+98,957
+340% +$1.15M 0.01% 865
2024
Q4 		$461K Buy
+29,146
New +$1.51M ﹤0.01% 1162
2022
Q4 		– Sell
-9,620
Closed -$362K – 1329
2022
Q3 		$362K Buy
+9,620
New +$333K ﹤0.01% 880

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return